Cancer treatment is on the brink of a revolutionary shift, and the University of Missouri (Mizzou) is at the forefront of this transformation. Imagine a world where doctors can precisely target cancer cells with radiation, minimizing damage to healthy tissue—this is no longer science fiction. Mizzou has just enrolled its first patient in a groundbreaking clinical trial testing a nuclear medicine device that promises to do just that. But here's where it gets even more exciting: this isn’t just another experimental treatment—it’s a game-changer for patients with advanced liver cancer.
Researchers at Mizzou have begun treating liver cancer patients with a cutting-edge technology called Eye90 microspheres. On February 9, the first patient received this treatment at the Ellis Fischel Cancer Center, marking a significant milestone in the fight against unresectable liver tumors, particularly hepatocellular carcinoma and metastatic colorectal cancer. But here’s where it gets controversial: while traditional treatments often rely on a 'shoot and hope' approach, Eye90 microspheres are designed to be radiopaque, meaning they’re visible on CT scans. This allows doctors to navigate and target tumors with unprecedented precision—a concept that’s sparking debates about the future of radiation therapy.
These microspheres, manufactured exclusively at the University of Missouri Research Reactor (MURR), are embedded with yttrium-90 (Y-90), a radioisotope long used in cancer treatment. However, traditional Y-90 beads were invisible once inside the body, leaving doctors to guess where the radiation was landing. Eye90 changes the game entirely. By being radiopaque, these beads provide a visual roadmap, ensuring radiation is delivered exactly where it’s needed. This innovation not only maximizes the destruction of cancer cells but also reduces the risk to healthy liver tissue—a win-win for patients.
And this is the part most people miss: Mizzou’s leadership in this field isn’t new. Since the 1980s, the university has been a pioneer in glass microsphere technology, starting with the development of TheraSphere. This legacy established MURR as the sole U.S. producer of these life-saving beads, a position it still holds today. Now, in partnership with ABK Biomedical, MURR is producing the next-generation Eye90 microspheres, ensuring a reliable domestic supply chain for both research and clinical trials.
Before reaching human trials, Eye90 underwent rigorous testing, starting with small animal models and progressing to a successful clinical trial in dogs with naturally occurring liver tumors. Led by Dr. Jeffrey Bryan at the College of Veterinary Medicine, these studies used advanced PET imaging to track treatment success, bridging the gap between lab and clinic. This meticulous approach provided the critical evidence needed to move forward with human trials.
The current clinical trial involves a single administration of Eye90 microspheres followed by a year-long observation period. Researchers will closely monitor how tumors respond to the treatment and assess improvements in patients’ quality of life. The ultimate goal? To secure broad regulatory approval, offering a new lifeline to patients with advanced liver cancer.
As Ryan Davis, associate professor of clinical radiology at Mizzou’s School of Medicine, aptly stated, ‘Studies like this provide early availability of therapies for our patients and continue our leadership in translational research. We are excited to be part of this study because we recognize the growing significance of targeted radiotherapy for metastatic tumors.’
But here’s the question that’s dividing experts: Is this the future of cancer treatment, or just another step in a long journey? Could this precision approach redefine how we tackle not just liver cancer, but other cancers as well? We’d love to hear your thoughts—do you think Eye90 microspheres could revolutionize cancer therapy, or is there still too much uncertainty? Share your opinions in the comments below!
